产品编号 |
COV363 |
产品名称 |
Recombinant COVID-19/SARS-CoV-2 Spike RBD protein, mFc Tag |
规格 |
100ug/¥2,850; 1mg/¥11,500; Bulk inquiry |
物种 |
COVID-19/2019-nCoV |
宿主 |
Mammalian Cells |
内毒素水平 |
< 0.1EU per μg protein as determined by the LAL method. |
缓冲体系 |
0.01M PBS, pH7.4 |
纯化方式 |
Ni+ Affinity & SEC-HPLC |
产品背景 |
A novel severe acute respiratory syndrome (SARS)-like coronavirus (SARS-CoV-2) recently emerged and is rapidly spreading in humans, causing COVID-191,2. A key to tackling this pandemic is to understand the receptor recognition mechanism of the virus, which regulates its infectivity, pathogenesis and host range. SARS-CoV-2 and SARS-CoV recognize the same receptor—angiotensin-converting enzyme 2 (ACE2)—in humans. Researchers determined the crystal structure of the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2 (engineered to facilitate crystallization) in complex with ACE2. In comparison with the SARS-CoV RBD, an ACE2-binding ridge in SARS-CoV-2 RBD has a more compact conformation; moreover, several residue changes in the SARS-CoV-2 RBD stabilize two virus-binding hotspots at the RBD–ACE2 interface. These structural features of SARS-CoV-2 RBD increase its ACE2-binding affinity. Additionally, we show that RaTG13, a bat coronavirus that is closely related to SARS-CoV-2, also uses human ACE2 as its receptor. |
保存条件 |
Store the lyophilized powder at 4°C for one week and -20°C to -80°C for long time. Store the liquid form at -80°C. Avoid multiple freeze/thaw cycles. |
备注 |
This product is used for research use only. Not for human or diagnostic use. |